NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

I think you are already seeing a lot of these risks considered in the current market prices.

As ATLnsider pointed out, there was a good chance the cost concerns brought up at yesterday's presentation were mostly directed towards nvcr as their costs are up to 5x at 5 years... and they have already been declined in the UK.

Flaskworks, if approved, will certainly alleviate any cost concerns for NWBO, imo.

I don't see the majority of these concerns applying to the US market.